AstraZeneca’s chief executive, David Brennan, was elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the industry group's annual meeting on April 3.
UK contract research organisation (CRO) Cyprotex has appointed Simon Bury as its chief commercial officer. Bury joins Cyprotex from Shanghai ChemPartner, where he was director of business development.
Ecron Acunova, a CRO operating out of Germany, India and the US, has named Dr. Antal Hajos as managing director and CEO Europe. Hajos will have overall responsibility for all business, strategic and operational aspects of the European operations.
Health Decisions, a CRO specialising in adaptive solutions for clinical development, has named Rich Podurgal as its chief human resources officer.
Piramal Healthcare has appointed Nandini Piramal on the board of the company as an executive director.
Sygnature Chemical Services of the UK, which provides of medicinal and synthetic chemistry and chemical library services, has named Dr. Paul Clewlow as senior vice president, business development, and as an executive member of its board of directors.
At eClinical specialist Phase Forward, Christopher Menard, formerly vice president of finance, has succeeded Rodger Weismann as senior vice president and chief financial officer.
At India’s Wockhardt, Habil Khorakiwala has stepped down from the managing director post in favour of his son Murtaza Khorakiwala. Meanwhile another son, Hozaifa Khorakiwala, has been named an executive director of the firm.
Bioprocessing company Xcellerex has appointed David Williams, retired chairman and CEO of Sanofi Pasteur, to its board of directors.
Seigo Kashii, has been appointed president and CEO of the North American subsidiary of Astellas Pharma. His predecessor, Yoshihiko Hatanaka, will become the chief strategy officer and chief financial officer at Astellas Pharma in Japan.